OKUR SCHEDULE 13G/A: SEC filing

Biotechnology Value Fund and affiliated entities

Filed with the SEC on · accession 0000921895-26-003184

OKUR filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator).

Summary of the filing

Biotechnology Value Fund and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 9.99% of OnKure Therapeutics' Class A Common Stock as of September 30, 2026, including shares underlying pre-funded warrants that are currently blocked from exercise.

Key details

Shares beneficially owned by BVF Partners L.P. (aggregate)$4.0M
Shares beneficially owned by Biotechnology Value Fund, L.P.$2.1M
Shares beneficially owned by Biotechnology Value Fund II, L.P.$1.6M
Shares beneficially owned by Biotechnology Value Trading Fund OS LP$279K
Shares underlying pre-funded warrants held by Reporting Persons and Partners Managed Account$2.1M
Reporting person / beneficial ownerBiotechnology Value Fund, L.P.
General partner of bvfBVF I GP LLC
Reporting person / beneficial ownerBiotechnology Value Fund II, L.P.
General partner of bvf2BVF II GP LLC
Reporting person / beneficial ownerBiotechnology Value Trading Fund OS LP
General partner of trading fund osBVF Partners OS Ltd.
Sole member of bvf gp and bvf2 gpBVF GP Holdings LLC
Investment manager of bvf, bvf2, and trading fund osBVF Partners L.P.
General partner of bvf partners l.p.BVF Inc.
IssuerOnKure Therapeutics, Inc.
Director and officer of bvf inc.Mark N. Lampert

✦ Ask GOAX AI about this filing — what it means for OKUR, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for OKUR?

Click here

Frequently asked questions

What did OKUR file with the SEC on Nov 16, 2026?

OKUR filed a SCHEDULE 13G/A (SEC filing). Biotechnology Value Fund and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 9.99% of OnKure Therapeutics' Class A Common Stock as of September 30, 2026, including shares underlying pre-funded warrants that are currently blocked from exercise.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

Other OKUR SEC filings

Get alerts when OKUR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days